Sun Pharmaceutical Industries Ltd To Invest $280 Million In Experimental Process Of Psoriasis Drug In-Licensed From Merck & Co.

NEW DELHI: Sun Pharmaceutical Industries Ltd., India's largest domestic drug maker by market capitalisation, plans to invest more than $280 million in the experimental psoriasis drug that it in-licensed from US-based Merck Sharp& Dohme (MSD) last month and hopes to commercialise globally by 2018, said industry consultants with direct knowledge of the matter.

This is part of Sun's attempt to invest in a basket of promising innovative products in select therapies to grow beyond generics and add new revenue streams,

Help employers find you! Check out all the jobs and post your resume.

Back to news